Testing a new eye injection for diabetic swelling
Part of Eyes & vision, Hormones & metabolism clinical trials.
This study tests different doses of a new medicine (BI 3812465) injected into the eye to treat diabetic macular edema—swelling in the back of the eye caused by diabetes that can blur vision. The trial measures how safe the medicine is and how well patients tolerate it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have diabetic macular edema (DME) confirmed by eye imaging, with swelling thickness of at least 320 micrometers
- Have type 1 or type 2 diabetes that is being treated, with a recent blood sugar control measure (HbA1c) below 12%
- Be at least 18 years old and able to sign consent
- Have clear enough eye structures and ability to hold your eye still for imaging tests
- Have both eyes with adequate vision for daily functioning (not dependent on just one eye)
- If able to have children, agree to use effective birth control during the study; men should use condoms or abstain to prevent pregnancy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (RO7823653) given as an eye injection for people with diabetic macular edema, a condition where swelling in the retina harms vision. It aims to see if the drug is safe and how the body processes it.
This trial compares a new treatment (EYP-1901, given as an injection) to a standard injection (aflibercept) for people with diabetic macular edema. It aims to see which works better at reducing swelling and improving vision.
This Phase 3 study compares a new eye injection (RC28-E) with the standard treatment (aflibercept) for diabetic macular edema, which is swelling in the central retina that affects vision. It aims to see whether the new treatment works as well and is safe.
This trial tests an investigational drug called CU06-1004 for people with diabetic macular edema (swelling in the center of the retina caused by diabetes). It aims to see if the drug can improve vision and reduce swelling.
This Phase 1 study tests the safety and early effectiveness of OCU200 eye injections in people with diabetic macular edema (DME) that affects the center of vision. It may help by reducing the eye swelling that blurs vision from diabetes.
This early-phase trial tests a new implant (EC-104) that goes inside the eye to treat diabetic macular edema (DME), a condition that causes blurry vision from fluid buildup. The implant slowly releases medicine over time, and the study will see if it is safe and helpful for people with DME.
Hear when a new Diabetic Macular Edema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.